Coenzyme drugs are nucleotide derivatives that participate in the synthesis and metabolism of phospholipids and nucleic acids in the body. They are intermediate products and energy sources for brain phospholipid synthesis and nucleic acid metabolism.

This product is an immunomodulatory drug. It has the function of regulating and enhancing the cellular immune function of the human body and can promote the maturation of T-lymphocytes.

Pharmacodynamics: This product is an immunomodulatory drug. It has the function of regulating and enhancing the cellular immune function of the human body and can promote the maturation of T-lymphocytes.

This product directly acts on the endogenous fibrinolytic system, catalyzing the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis.

This product acts directly on the endogenous fibrinolytic system and can catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis. After intravenous infusion of this product, the activity of plasmin in the patient's body is significantly increased; after a few hours of discontinuation of the drug, the activity of plasmin returns to the original level. However, the decrease in plasma fibrin or fibrinogen levels and the increase in their degradation products can last for 12-24 hours. This product shows a significant correlation between the thrombolytic effect and the drug dose and the time window of administration.

This product is a selective 5-HT3 receptor antagonist. Its mechanism of action may be to antagonize the 5-HT3 receptors in the peripheral vagus nerve endings and central chemoreceptor areas, thereby blocking the vomiting reflex caused by factors such as chemotherapy and surgery that promote the release of 5-HT from intestinal chromaffin cells and excite the vagus afferent nerves. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation.